" class="no-js "lang="en-US"> Martin Renner - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Martin Renner

Martin Renner

About Martin Renner

Martin took over the management as CEO of Develco Pharma Schweiz AG and subsidiaries in January 2020 in order to successfully lead the Develco Group into the next decade with his wealth of experience.

Martin is a pharmacist and studying pharmacy in Düsseldorf. He received his PhD in Pharmaceutical Technology in 2004.

He started his career in a global pharmaceutical company. In a wide variety of international management positions in the group, he took over various site managements with different dosage forms from 2013.

Based on his management experience, his pharmaceutical-technological know-how as well as his friendly and charming as well as purposefully structured management style, he has already made positive progress on several milestones at Develco since the beginning of the year.

Related Story

Clinical Trials

 HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-resistant Depression (TRD) | Pharmtech Focus

HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-resistant Depression (TRD)

April 1 2022

HMNC Brain Health (“HMNC” or the “Company”), a global clinical stage biopharmaceutical company pioneering the […]